This document discusses the role of microRNAs (miRNAs) in disease. It describes two studies: 1) A human study showing that a silent mutation impairs miRNA binding, increasing Crohn's disease risk. This provides evidence that silent mutations can functionally impact miRNA regulation and cause disease. 2) A mouse study demonstrating tumor dependence on miR-21, highlighting the role of miRNAs as disease drivers. Targeting these miRNA drivers may help develop new drugs. The document argues that further investigation is needed into how genetic variants alter miRNA regulation and contribute to disease.
MODULATING EFFECT OF ESTRADIOL, IFN-γ AND T-CELLS ON ESTROGEN RECEPTORS EXPRE...Татьяна Гергелюк
The fight against malignant neoplasms is one of the most pressing problems in biology and medicine. Breast cancer (BC) takes the first place in the structure of cancer incidence and cause of death of thousands women in Ukraine
every year. One of the main treatments for breast cancer along with chemotherapy and radiotherapy, is a hormonal influence on sensitive cells of the tumor. 75% of all breast tumors is hormone sensitive, because express estrogen (ER)
and progesterone receptors (PR). The most effective drugs are anti-estrogen substances, the most famous of them - tamoxifen (TAM). The level of PR and ER is an important parameter of effectiveness of TAM. Loss of sensitivity of
tumor to TAM over time may be associated with decreasing of the number of steroid receptors. In this regard, it is necessary to find methods of influence on receptor status of cells BC.
MODULATING EFFECT OF ESTRADIOL, IFN-γ AND T-CELLS ON ESTROGEN RECEPTORS EXPRE...Татьяна Гергелюк
The fight against malignant neoplasms is one of the most pressing problems in biology and medicine. Breast cancer (BC) takes the first place in the structure of cancer incidence and cause of death of thousands women in Ukraine
every year. One of the main treatments for breast cancer along with chemotherapy and radiotherapy, is a hormonal influence on sensitive cells of the tumor. 75% of all breast tumors is hormone sensitive, because express estrogen (ER)
and progesterone receptors (PR). The most effective drugs are anti-estrogen substances, the most famous of them - tamoxifen (TAM). The level of PR and ER is an important parameter of effectiveness of TAM. Loss of sensitivity of
tumor to TAM over time may be associated with decreasing of the number of steroid receptors. In this regard, it is necessary to find methods of influence on receptor status of cells BC.
Carcinogenesis refers to the process by which a normal cell is transformed into a malignant cell and repeatedly divides to become a cancer
Chemicals which initiate this process is called chemical carcinogens
Chemicals which increase the effectiveness of carcinogens is called co-carcinogens
REGULATORY BACKGROUND
ROLE OF PROTO-ONCOGENES AND TUMOR SUPPRESSOR GENES
ACTIVATION OF PROTO ONCOGENES
OXIDATIVE STRESS IN CARCINOGENESIS
OECD guidelines
451- Carcinogenecity studies
453- Combined chronic toxicity/carcinogenecity
ICH guidelines
S1A- Guideline on the need for carcinogenicity studies of
pharmaceuticals
S1B- Testing for carcinogenicity of pharmaceuticals
S1C- Dose selection for carcinogenicity studies of pharmaceuticals
Audio and slides for this presentation are available on YouTube: http://youtu.be/e_KVYJX2GTs
Have you ever wondered about your genetic predisposition to cancer? How cancer evolves in families? Or how cancer cells differ from normal cells in your body? Join Judy Garber, MD, MPH, director of the Center for Cancer Genetics and Prevention at Dana-Farber Cancer Institute, as she explores the basics of cancer genetics, DNA mutations, genetic screening, management, and more.
An oncogene is a gene that has the potential to cause cancer. In tumor cells, they are mutated or expressed at high levels. Most normal cells undergo a programmed form of rapid cell death (apoptosis) when critical functions are altered.
INTRODUCTION
HISTORY
GENES INVOLVED IN CANCER
ONCOGENES
TUMOUR SUPPRESSOR GENES
ONCOGENE
INTRODUCTION
TYPES
ACTIVATION OF PROTO ONCOGENES
FUNCTION
TUMOUR SUPPRESSOR GENES
INTRODUCTION
EXAMPLE
RB GENE
TP53 GENE
CONCLUSION
REFERENCES
Currently, around 11 million people are living with a tumour that contains an inactivating mutation of TP53 (the human gene that encodes p53) and another 11 million have tumours in which the p53 pathway is partially abrogated through the inactivation of other signalling or effector components. The p53 pathway is therefore a prime target for new cancer drug development, and several original approaches to drug discovery that could have wide applications to drug development are being used. In one approach, molecules that activate p53 by blocking protein–protein interactions with MDM2 are in early clinical development. Remarkable progress has also been made in the development of p53-binding molecules that can rescue the function of certain p53 mutants.
Carcinogenesis refers to the process by which a normal cell is transformed into a malignant cell and repeatedly divides to become a cancer
Chemicals which initiate this process is called chemical carcinogens
Chemicals which increase the effectiveness of carcinogens is called co-carcinogens
REGULATORY BACKGROUND
ROLE OF PROTO-ONCOGENES AND TUMOR SUPPRESSOR GENES
ACTIVATION OF PROTO ONCOGENES
OXIDATIVE STRESS IN CARCINOGENESIS
OECD guidelines
451- Carcinogenecity studies
453- Combined chronic toxicity/carcinogenecity
ICH guidelines
S1A- Guideline on the need for carcinogenicity studies of
pharmaceuticals
S1B- Testing for carcinogenicity of pharmaceuticals
S1C- Dose selection for carcinogenicity studies of pharmaceuticals
Audio and slides for this presentation are available on YouTube: http://youtu.be/e_KVYJX2GTs
Have you ever wondered about your genetic predisposition to cancer? How cancer evolves in families? Or how cancer cells differ from normal cells in your body? Join Judy Garber, MD, MPH, director of the Center for Cancer Genetics and Prevention at Dana-Farber Cancer Institute, as she explores the basics of cancer genetics, DNA mutations, genetic screening, management, and more.
An oncogene is a gene that has the potential to cause cancer. In tumor cells, they are mutated or expressed at high levels. Most normal cells undergo a programmed form of rapid cell death (apoptosis) when critical functions are altered.
INTRODUCTION
HISTORY
GENES INVOLVED IN CANCER
ONCOGENES
TUMOUR SUPPRESSOR GENES
ONCOGENE
INTRODUCTION
TYPES
ACTIVATION OF PROTO ONCOGENES
FUNCTION
TUMOUR SUPPRESSOR GENES
INTRODUCTION
EXAMPLE
RB GENE
TP53 GENE
CONCLUSION
REFERENCES
Currently, around 11 million people are living with a tumour that contains an inactivating mutation of TP53 (the human gene that encodes p53) and another 11 million have tumours in which the p53 pathway is partially abrogated through the inactivation of other signalling or effector components. The p53 pathway is therefore a prime target for new cancer drug development, and several original approaches to drug discovery that could have wide applications to drug development are being used. In one approach, molecules that activate p53 by blocking protein–protein interactions with MDM2 are in early clinical development. Remarkable progress has also been made in the development of p53-binding molecules that can rescue the function of certain p53 mutants.
Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in ...Enrique Moreno Gonzalez
Active vitamin D analogs that are less toxic than calcitriol can be useful in the combined treatment of patients suffering from colon cancer. In the present study we demonstrate, for the first time in an in vivo model system, the biological effect of combined therapy using 5-fluorouracil (5-FU) along with vitamin D analog PRI-2191 (tacalcitol, 1,24-dihydroxyvitamin D3) or PRI-2205 (5,6-trans-isomer of calcipotriol) on colon cancer.
Introduction to Cancer
Stem cells and cancer cells
major pathways that lead to formation of tumors.
Tumor Supressors
Colon cancer to prove Knudson hypothesis.
The modern treatments available to treat cancer.
micro rna world is new emrging reaserch area in the scientist community and give the way to find the solution of more comlex isssues related to furious diseases .....
miRNAs: Role of Post-Transcriptional Regulation of NLRP3 Inflammasomes in The...suppubs1pubs1
Inflammasomes are multiprotein complexes consist of having nucleotide binding domain and leucine rich repeat with the pyrin and HIN domain family. The NLRP3 inflammasome one of these members of family. It is activated upon sensing microbes or danger associated molecular pattern. NLRP3 inflammasome activation leads to activation of caspase 1 which is in turn activate proinflmmatory cytokines/chemomokines.
Conferencia de la Dra. Ana María Roa, Bióloga Molecular, sobre Epigenética, impartida en la Universidad Popular Carmen de Michelena de Tres Cantos el 1 de marzo de 2013.
Más información en:
http://www.universidadpopularc3c.es/index.php/actividades/conferencias/event/448-conferencia-una-revision-de-los-conocimientos-fundamentales-de-la-biologia-de-la-celula-la-epigenetica
Similar to miRNAs in the spotlight: Making 'silent' mutations speak up. (20)
Purpose: An inherited mutation in KRAS (LCS6-variant or rs61764370) results in altered control of the KRAS oncogene. We studied this biomarker’s correlation to anti-EGFR monoclonal antibody (mAb) therapy
response in patients with metastatic colorectal cancer.
Experimental Design: LCS6-variant and KRAS/BRAF mutational status was determined in 512 patients
with metastatic colorectal cancer treated with salvage anti-EGFR mAb therapy, and findings correlated with
outcome. Reporters were tested in colon cancer cell lines to evaluate the differential response of the LCS6-
variant allele to therapy exposure.
Results: In this study, 21.2% (109 of 512) of patients with metastatic colorectal cancer had the LCS6-
variant (TG/GG), which was found twice as frequently in the BRAF-mutated versus the wild-type (WT) group
(P = 0.03). LCS6-variant patients had significantly longer progression- free survival (PFS) with anti-EGFR
mAb monotherapy treatment in the whole cohort (16.85 vs. 7.85 weeks; P = 0.019) and in the double WT
(KRAS and BRAF) patient population (18 vs. 10.4 weeks; P = 0.039). Combination therapy (mAbs plus
chemotherapy) led to improved PFS and overall survival (OS) for nonvariant patients, and brought their
outcome to levels comparable with LCS6-variant patients receiving anti-EGFR mAb monotherapy. Combination
therapy did not lead to improved PFS or OS for LCS6-variant patients. Cell line studies confirmed a
unique response of the LCS6-variant allele to both anti-EGFR mAb monotherapy and chemotherapy.
Conclusions: LCS6-variant patients with metastatic colorectal cancer have an excellent response to anti-EGFR
mAb monotherapy, without any benefit from the addition of chemotherapy. These findings further confirm
the importance of thismutation as a biomarker of anti-EGFR mAb response in patients with metastatic colorectal cancer, and warrant further prospective confirmation.